Literature DB >> 6515328

Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.

A Manoharan, W R Pitney.   

Abstract

12 patients with symptomatic chronic myelofibrosis were treated with either busulphan or 6-thioguanine. Therapy was without significant side effects and resulted in a reduction in the size of liver and spleen and an improvement in well-being in all cases. In 7 patients the Hb value rose and the extent of marrow fibrosis was reduced in the 5 patients in whom bone marrow examination was repeated after treatment. Chemotherapy is an effective and safer alternative to splenectomy in patients with myelofibrosis with symptomatic anaemia, symptomatic splenomegaly or constitutional symptoms such as fever, weight loss and night sweats.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6515328     DOI: 10.1111/j.1600-0609.1984.tb00724.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  9 in total

Review 1.  New drugs for the treatment of myelofibrosis.

Authors:  Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

2.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 3.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Adrenal extramedullary hematopoiesis: report on a pediatric case and update of the literature.

Authors:  A B Porcaro; G Novella; S Z Antoniolli; G Martignoni; M Brunelli; P Curti
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.

Authors:  J Thiele; H M Kvasnicka; N Niederle; T K Zirbes; M Schmidt; J Dammasch; B R Meuter; L D Leder; O Kloke; V Diehl
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

6.  Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

Authors:  B Hoff; J H Lumsden; V E Valli; S A Kruth
Journal:  Can Vet J       Date:  1991-06       Impact factor: 1.008

Review 7.  Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

Review 8.  Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Authors:  Jasleen Randhawa; Alen Ostojic; Radovan Vrhovac; Ehab Atallah; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2012-08-01       Impact factor: 17.388

Review 9.  Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Authors:  Raoul Tibes; Ruben A Mesa
Journal:  J Hematol Oncol       Date:  2014-03-05       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.